Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma

References

• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. .
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817–1826. .
   PubMed Web of Science ®Google Scholar
• Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–1867. .
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799. .
   PubMed Web of Science ®Google Scholar
• Sehn LH, Martelli M, Trněný M, et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13:71.
   Web of Science ®Google Scholar
• Vitolo U, Witzig TE, Gascoyne RD, et al. ROBUST: first report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol. 2019;37:36–37.
   Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295.
   PubMed Web of Science ®Google Scholar
• Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649–662. .
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–3127. .
   PubMed Web of Science ®Google Scholar
• Jaeger U, Trneny M, Melzer H, et al. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015;100(7):955–963. .
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Tilly H, Da Silva MG, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473–2481. .
   PubMed Web of Science ®Google Scholar
• Crump M, Leppä S, Fayad L, et al. Randomized, double-blind, phase 3 trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-Cell lymphoma. J Clin Oncol. 2016;34(21):2484–2492. .
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. .
   PubMed Web of Science ®Google Scholar
• Leslie LA, Younes A. Antibody-drug conjugates in hematologic malignancies. Am Soc Clin Oncol Educ Book. 2013. DOI:10.1200/EdBook_AM.2013.33.e108.
   Google Scholar
• Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12(5):329–332.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Hamadani M, Radford J, et al. A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody–drug conjugate, in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2019;25(23):6986–6994. .
   PubMed Web of Science ®Google Scholar
• Trnĕny M, Verhoef G, Dyer MJS, et al. A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018;103(8):1351–1358. .
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Flinn IW, Advani R, et al., Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019‘6(5):e254–e265.
   PubMed Web of Science ®Google Scholar
• Stathis A, Flinn IW, Madan S, et al. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest New Drugs. 2018;36(5):869–876. .
   PubMed Web of Science ®Google Scholar
• Vaisitti T, Jessen K, Vo -T-T, et al. Vls-101 is a novel therapeutic antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) in richter’s syndrome (RS). Blood. 2019;134(Supplement_1):2856.
   Google Scholar
• Cabezudo E, Carrara P, Morilla R, et al. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica. 1999;84(5):413–418.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Musto P, Cascavilla N, et al. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol. 2000;64(4):275–281. .
   PubMed Web of Science ®Google Scholar
• Olejniczak SH, Stewart CC, Donohue K, et al. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest. 2006;35(1):93–114. .
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–784. .
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kubagawa H, Cooper MD. Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A. 1992;89(18):8522–8526.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Chandra Sekar M, Kubagawa H, et al. Signal transduction in human B cells initiated via Ig β ligation. Int Immunol. 1993;5(10):1309–1315. .
   PubMed Web of Science ®Google Scholar
• Vasile S, Coligan JE, Yoshida M, et al. Isolation and chemical characterization of the human B29 and mb-1 proteins of the B cell antigen receptor complex. Mol Immunol. 1994;31(6):419–427. .
   PubMed Web of Science ®Google Scholar
• Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721–2729. .
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29(7):1578–1586. .
   PubMed Web of Science ®Google Scholar
• Meffre E, Casellas R, Nussenzweig MC. Antibody regulation of B cell development. Nat Immunol. 2000 ;1(5):379–385.
   Web of Science ®Google Scholar
• Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296(5573):1641–1642.
   PubMed Web of Science ®Google Scholar
• Craxton A, Otipoby KL, Jiang A, et al. Signal transduction pathways that regulate the fate of B lymphocytes. Adv Immunol. 1999;73:79–152.
   PubMed Web of Science ®Google Scholar
• Yam-Puc JC, Zhang L, Zhang Y, et al. Role of B-cell receptors for B-cell development and antigen-induced differentiation [version 1; referees: 2 approved]. Wellcome Open Res. 2018. F1000 Research Ltd.
   Google Scholar
• Dal Porto JM, Gauld SB, Merrell KT, et al. B cell antigen receptor signaling 101. Mol Immunol. 2004;41(6–7):599–613. .
   PubMed Web of Science ®Google Scholar
• Packard TA, Cambier JC. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation. F1000Prime Rep. 2013;5:40.
   PubMedGoogle Scholar
• Drake JR, Lewis TA, Condon KB, et al. Involvement of MIIC-like late endosomes in B cell receptor-mediated antigen processing in murine B cells. J Immunol. 1999;162(2):1150–1155.
   PubMed Web of Science ®Google Scholar
• Polson AG, Yu SF, Elkins K, et al., Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007‘110(2):616–623.
   PubMed Web of Science ®Google Scholar
• Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):2358–2364. .
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, et al., Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017‘16(5):315–337.
   PubMed Web of Science ®Google Scholar
• Wiggins B, Liu-Shin L, Yamaguchi H, et al. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and Immunoglobulin G2 antibody-drug conjugates. J Pharm Sci. 2015;104(4):1362–1372.
   PubMed Web of Science ®Google Scholar
• McDonagh CF, Kim KM, Turcott E, et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther. 2008;7(9):2913–2923.
   PubMed Web of Science ®Google Scholar
• Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4). 10.1042/BSR20150089
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925–932.
   PubMed Web of Science ®Google Scholar
• Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184–189. .
   PubMed Web of Science ®Google Scholar
• Polakis P Arming antibodies for cancer therapy. Curr Opin Pharmacol. 2005;5(4):382–387.
   Google Scholar
• Lambert JM Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005;5(5):543–549.
   Google Scholar
• Garnett MC. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev. 2001;53(2):171–216.
   PubMed Web of Science ®Google Scholar
• Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibody - Calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002;13(1):40–46. .
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214–3221. .
   PubMed Web of Science ®Google Scholar
• Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2 Pt 1):843–852.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114–124. .
   PubMed Web of Science ®Google Scholar
• Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426–4433. .
   PubMed Web of Science ®Google Scholar
• Dere R, Yi JH, Lei C, et al. PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis. 2013;5(9):1025–1040. .
   PubMed Web of Science ®Google Scholar
• Polson AG, Williams M, Gray AM, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin’s lymphoma. Leukemia. 2010;24(9):1566–1573. .
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Antibody-drug conjugates present and future. MAbs. 2014;6(1):15–17.
   PubMed Web of Science ®Google Scholar
• Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–637.
   PubMed Web of Science ®Google Scholar
• Salomon PL, Singh R. Sensitive ELISA method for the measurement of catabolites of antibody-drug conjugates (ADCs) in target cancer cells. Mol Pharm. 2015;12(6):1752–1761.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Salles GA, Czuczman MS, et al., Final results of a phase I study of the anti-CD79b antibody-drug conjugate DCDS4501A in relapsed or refractory (R/R) B-cell non-hodgkin lymphoma (NHL). Blood. 2013‘122(21):4400.
   Google Scholar
• Palanca-Wessels MCA, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–715. .
   PubMed Web of Science ®Google Scholar
• Lu D, Gillespie WR, Girish S, et al. Time-to-event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens. CPT Pharmacometrics Syst. Pharmacol. 2017;6:401–408.
   Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
   Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Bartlett NL, et al., Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. Lancet Oncol. 2019‘20(7):998–1010.
   PubMed Web of Science ®Google Scholar
• Tilly H, Flowers C, Friedberg JW, et al. POLARIX: a phase 3 study of polatuzumab vedotin (Pola) plus R-CHP versus R-CHOP in patients with untreated DLBCL. Hematol Oncol. 2019;37:68–70.
   Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–2856. .
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–3459. .
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP (R2CHOP) improves outcomes in newly diagnosed diffuse large b-cell lymphoma (DLBCL): first report of ECOG-ACRIN1412 a randomized phase 2 US intergroup study of R2CHOP vs R-CHOP. Hematol Oncol. 2019;37:37–38.
   Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642. .
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. .
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar